By sequestering RANKL, denosumab mimics the physiological action of osteoprotegerin (OPG), effectively arresting the ‘vicious cycle’ of bone destruction driven by tumor-derived cytokines (e.g., PTHrP) (40, 41). Here, TNFSF11 is linked to neoplasm.